Last reviewed · How we verify

NCT07301333

A Phase 1 Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food on the Bioavailability of HRS-6257 in Healthy Subjects

Recruiting now Phase 1 Last updated 1 April 2026
What this trial tests

Phase 1 trial testing HRS-6257 in Pain in 80 participants. Currently enrolling.

Timeline
30 December 2025
Primary endpoint
1 May 2026
1 May 2026

Quick facts

Lead sponsorShanghai Hengrui Pharmaceutical Co., Ltd.
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment80
Start date30 December 2025
Primary completion1 May 2026
Estimated completion1 May 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 55, any sex, with Pain. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pain

Currently open trials in the same condition.

Other Shanghai Hengrui Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07301333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing